Early clinical reports indicates that C3 inhibition therapy holds potential anti-inflammatory properties in COVID-19 (Mastaglio et al., 2020; Satyam and Tsokos, 2020) and anti-complement C5 therapy in patients with severe COVID-19 lead to a drop in inflammatory markers and a successful recovery (Diurno et al., 2020; Satyam and Tsokos, 2020). The gene discussed is C5; the disease is COVID-19.